Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.435
-0.135 (-2.95%)
Jun 8, 2026, 12:36 PM EDT - Market open
Myriad Genetics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 124.4 | 149.6 | 102.4 | 132.1 | 56.9 | 257.4 |
Short-Term Investments | - | - | - | 8.8 | 58 | 81.4 |
Cash & Short-Term Investments | 124.4 | 149.6 | 102.4 | 140.9 | 114.9 | 338.8 |
Cash Growth | 35.51% | 46.09% | -27.32% | 22.63% | -66.09% | 124.82% |
Accounts Receivable | 123.8 | 115.3 | 121.2 | 114.3 | 101.6 | 91.3 |
Inventory | 27.9 | 30.6 | 27.5 | 22 | 20.1 | 15.3 |
Other Current Assets | 36.7 | 37.1 | 46.9 | 36.4 | 38 | 39.4 |
Total Current Assets | 312.8 | 332.6 | 298 | 313.6 | 274.6 | 484.8 |
Net Property, Plant & Equipment | 162.5 | 163.4 | 172.4 | 180.6 | 187.3 | 125.3 |
Other Intangible Assets | 145.7 | 153.4 | 262.4 | 349.5 | 379.7 | 404.1 |
Goodwill | 47.1 | 51.6 | 286.3 | 287.4 | 286.8 | 239.2 |
Long-Term Investments | - | - | - | - | 54.8 | 59 |
Other Long-Term Assets | 5.6 | 5.6 | 8.5 | 15.4 | 15.5 | 8.3 |
Total Assets | 673.7 | 706.6 | 1,028 | 1,147 | 1,199 | 1,321 |
Accounts Payable | 32.6 | 30 | 32.3 | 25.8 | 28.8 | 29.6 |
Accrued Expenses | 90.5 | 96.9 | 119 | 113.9 | 94.3 | 161.7 |
Current Portion of Leases | 7.1 | 6.9 | 12.8 | 16.2 | 14.1 | 13 |
Total Current Liabilities | 130.2 | 133.8 | 164.1 | 155.9 | 137.2 | 204.3 |
Long-Term Debt | 120.3 | 119.9 | 39.6 | 38.5 | - | - |
Long-Term Leases | 84.1 | 83 | 87.9 | 97.4 | 130.9 | 79.3 |
Other Long-Term Liabilities | 1.7 | 1.9 | 34.9 | 71.5 | 44.8 | 69.3 |
Total Long-Term Liabilities | 206.1 | 204.8 | 162.4 | 207.4 | 175.7 | 148.6 |
Total Liabilities | 336.3 | 338.6 | 326.5 | 363.3 | 312.9 | 352.9 |
Common Stock | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 |
Additional Paid-in Capital | 1,493 | 1,489 | 1,458 | 1,416 | 1,260 | 1,226 |
Accumulated Other Comprehensive Income | 0.7 | 0.8 | -0.8 | -3.7 | -8.9 | -5.1 |
Retained Earnings | -1,157 | -1,123 | -756.8 | -629.5 | -366.2 | -254.2 |
Shareholders' Equity | 337.4 | 368 | 701.1 | 783.2 | 885.8 | 967.8 |
Total Liabilities & Equity | 673.7 | 706.6 | 1,028 | 1,147 | 1,199 | 1,321 |
Total Debt | 211.5 | 209.8 | 140.3 | 152.1 | 145 | 92.3 |
Net Cash (Debt) | -87.1 | -60.2 | -37.9 | -11.2 | -30.1 | 246.5 |
Net Cash Per Share | -0.94 | -0.65 | -0.42 | -0.14 | -0.37 | 3.16 |
Book Value | 337.4 | 368 | 701.1 | 783.2 | 885.8 | 967.8 |
Book Value Per Share | 3.62 | 3.97 | 7.74 | 9.46 | 10.99 | 12.41 |
Tangible Book Value | 144.6 | 163 | 152.4 | 146.3 | 219.3 | 324.5 |
Tangible Book Value Per Share | 1.55 | 1.76 | 1.68 | 1.77 | 2.72 | 4.16 |